A genomic-led strategy to anticipate drug safety effects
PLOS Genetics · 16.07.2026 · 22 (7) · e1012211
DOI: 10.1371/journal.pgen.1012211 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, online erschienen am 16.07.2026. Verfasst von Brian R Ferolito und 29 weiteren Autor:innen. Beteiligte Einrichtung: Million Veteran Program (MVP) Coordinating Center, Veterans Affairs Healthcare System, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Genomics. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: U.S. Department of Veterans Affairs, U.S. Department of Energy, UK Medical Research Council.
Abstract (Originalsprache)
Safety-related issues account for approximately 25% of failures in new drug discovery programs. On top of that, many are discovered during post-marketing surveillance, significantly limiting drug utility and application. To proactively address these concerns, we developed a genetics-led strategy leveraging Mendelian Randomization (MR) across large-scale genetic datasets from the Million Veteran Program, FinnGen, and UK Biobank. By mapping genetic variants associated with gene expression and protein abundance to 1,449 harmonized human phenotypes, we systematically identified potential adverse drug reactions (ADR). Our extensive MR analysis, encompassing 16,915 protein-coding genes, demonstrated the capacity to predict hundreds of known ADR for approved medications, with approximately 40% corroborated by FDA Adverse Event Reporting System (FAERS) data. Additionally, we found significant enrichment of identified gene-mechanism pairs in clinical trials terminated early due to safety concerns, highlighting the clinical utility of genetics-informed safety prediction. Notably, immune-related pathways were prominently associated with ADR, indicating particular sensitivity within immune modulation targets. Our comprehensive atlas, integrating genetic evidence with pharmacological mechanisms, provides a robust predictive framework for anticipating drug safety, potentially enhancing decision-making in drug development and pharmacovigilance. An interactive web interface allowing filtering by gene, phenotype, drug phase, and mechanism of action is available at https://shiny.parse-health.org/safety/ .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Million Veteran Program (MVP) Coordinating Center, Veterans Affairs Healthcare System, Boston, Massachusetts, United States of America.
- Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
- Division of Aging, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
- The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
- Health Data Science Centre, Human Technopole, Milan, Italy.
- Centre for Human Technologies (CHT), Istituto Italiano di Tecnologia, Genova, Italy.
ORCID-Profile: Brian R Ferolito, Andrea R V R Horimoto, Kai Gravel-Pucillo, Claudia Giambartolomei, Danielle Rasooly, Liam Gaziano, Nicole Kosik, Harris Ioannidis, Giovanna Winicki, Claudia Langenberg, John C Whittaker, Barbara Zdrazil, Alexandre C Pereira
Förderung
- U.S. Department of Veterans Affairs
- U.S. Department of Energy
- UK Medical Research Council
Zitieren
APA
Ferolito, B. R., Horimoto, A. R. V. R., Gravel-Pucillo, K., Golden, D. J., Dashti, H., Giambartolomei, C., Rasooly, D., Matty, R., Gaziano, L., Tsepilov, Y., Costa, L., Kosik, N., Ioannidis, H., Karim, M., Winicki, G., Hunter, F., Langenberg, C., Whittaker, J. C., Million Veteran Program, …, & Pereira, A. C. (2026). A genomic-led strategy to anticipate drug safety effects. PLOS Genetics, 22(7), e1012211. https://doi.org/10.1371/journal.pgen.1012211
Vancouver
Ferolito BR, Horimoto ARVR, Gravel-Pucillo K, Golden DJ, Dashti H, Giambartolomei C, et al. A genomic-led strategy to anticipate drug safety effects. PLOS Genetics. 2026;22(7):e1012211. doi:10.1371/journal.pgen.1012211
BibTeX
@article{Ferolito2026,
author = {Ferolito, Brian R and Horimoto, Andrea R V R and Gravel-Pucillo, Kai and Golden, Daniel J and Dashti, Hesam and Giambartolomei, Claudia and Rasooly, Danielle and Matty, Rachael and Gaziano, Liam and Tsepilov, Yakov and Costa, Lauren and Kosik, Nicole and Ioannidis, Harris and Karim, Mohd and Winicki, Giovanna and Hunter, Fiona and Langenberg, Claudia and Whittaker, John C and Million Veteran Program, Million Veteran Program and Cai, Tianxi and Peloso, Gina M and Zdrazil, Barbara and Ghoussaini, Maya and Leach, Andrew R and Muralidhar, Sumitra and Smit, Ines A and Casas, Juan P and Gaziano, J Michael and Cho, Kelly and Pereira, Alexandre C},
title = {A genomic-led strategy to anticipate drug safety effects},
journal = {PLOS Genetics},
year = {2026},
volume = {22},
number = {7},
pages = {e1012211},
doi = {10.1371/journal.pgen.1012211}
}
EUVIMED